IndraLab

Statements

BTK inhibitor inhibits CYLD. 3 / 3
| 3
reach
"Previous researches in CLL indicated that BTK inhibitor ibrutinib could largely increase CYLD activity through increasing CYLD miRNA transcription, which could inhibit cells proliferation in CLL [XREF_BIBR]."
33827598
reach
"To sum up, these results indicated that BTK inhibitor promoted CYLD dependent apoptosis in rituximab resistant non-GCB-DLBCL cells."
33827598
reach
"BTK inhibitor PCI-32765 promoted CYLD dependent apoptosis in rituximab resistant non-GCB-DLBCL cells."
33827598